• PDF / 169,428 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 40 Downloads / 189 Views

DOWNLOAD

REPORT

---

1 S

Lack of efficacy and ulcerative colitis: case report A 42-year-old man exhibited lack of efficacy during treatment with methotrexate for psoriatic arthritis. Subsequently, he developed ulcerative colitis during treatment with secukinumab for psoriatic arthritis [routes not stated; not all dosages stated]. The man, who had psoriatic arthritis, started receiving secukinumab due to lack of response to methotrexate. He received secukinumab 150 mg/week (induction dose) followed by 150 mg/month (maintenance dose). His mother had ulcerative colitis. Approximately 3 weeks after initiation of secukinumab, he developed rectorrhagia and diarrhoeal stools. A colonoscopy was performed, which revealed the presence of inflammatory mucosal changes from the anal margin to the splenic flexture, with histology compatible with ulcerative colitis. The man’s treatment with secukinumab was discontinued. He was treated with golimumab and unspecified corticosteroids [outcome not stated]. Rodriguez Moncada R, et al. The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?. [Review]. Revista Espanola de Enfermedades Digestivas 111: 720-721, No. 9, 2019. Available from: URL: http://doi.org/10.17235/reed.2019.5841/2018 [Spanish; Summarised from a 803503504 translation]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823